Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 317,61 pts
-0.41%


Last updated : 17/11/2026 - 09h25
🏠 Home   ➤    Stock news

Valbiotis Raises €1.65 M in Bank Loans Without Dilution to Support Its Pharmacy Sales

The La Rochelle-based laboratory specializing in cardiometabolic health is using amortizing loans and receivables financing to support the ramp-up of its sales, particularly in pharmacies. Announced in a press release published on November 16, 2026, these resources are in addition to its existing cash, with no dilution for shareholders.


Valbiotis Raises €1.65 M in Bank Loans Without Dilution to Support Its Pharmacy Sales

Three Fixed-Rate Loans, Including One with a Deferred Repayment at Bpifrance

Valbiotis has obtained three fixed-rate loans, for a total of €1.65 M. Its two historical banks, Société Générale and BNP Paribas, each granted it €600 k over a term of four years.

The third loan, of €450 k, comes from Bpifrance. Its total term reaches eight years, with a three-year repayment deferral followed by a five-year amortization period.

Sébastien Peltier, Chairman of the Management Board, sees in this the illustration of “our ability to obtain financing suited to each stage of our development.” According to him, these resources give the company “the means to support, under the best conditions, the ramp-up of our sales, particularly in pharmacies.”

A €500 k Factoring Arrangement Linked to Payment Terms in Pharmacies

In parallel, Valbiotis has signed a factoring agreement with BNP Paribas Factor, with an authorized financing facility of €500 k. This ceiling may be increased at any time during the term of the contract, depending on business growth.

This arrangement is intended to finance the working capital requirement linked to trade receivables. According to the company, this requirement should increase with the expected rise in revenue in pharmacies, a channel where payment terms are 45 days end of month.

These financings supplement the €11.7 M in cash held as of June 30, 2026, which provide Valbiotis with a financing horizon through the end of 2027, excluding any additional source of financing. The company indicates that it can thus give priority to allocating its resources to the commercial rollout of its products.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0,8 millions d'euros
  • Quarterly revenue: 0,8 millions d'euros
  • Net income: -3,4 millions d'euros
Guidance from the release
  • « Valbiotis renonce par prudence à son ambition de chiffre d'affaires à 3 M€ sur l'ensemble de l'exercice 2026 » et retire ses ambitions 2027 et 2030

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours